- Tools for Investors
- Stock News
- Investing Ideas
- Econ & Policy
- Personal Finance
Sanofi-Aventis (NYSE:SNY): Current price $50.71
Late Thursday, France’s number-one drugmaker reported that its experimental Lemtrada remained effective in patients suffering from multiple sclerosis during the first year of an extension study. Relapse rates and sustained accumulation of disability remained low among patients who had been administered the treatment in previous clinical trials, and over 80 percent of patients did not receive a further course of Lemtrada during the first year of the extension study. Lemtrada is also known as alemtuzumab, and is a so-called monoclonal antibody administered to patients via infusions in two cycles at a 12-month interval. Sanofi obtained the drug through its $20.1 billion acquisition of the American biotech firm Genzyme Corp. in 2011.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
There's always a bull market in some sector! Find the best opportunities in commodities.